A Comparison of Glide Force Characteristics Between 2 Prefilled Insulin Lispro Pens

Rees, Tina M.; Lennartz, Amanda H.; Ignaut, Debra A.

doi:10.1177/1932296814567533

Cited by 16 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A literature search was conducted to support health state content and guide subsequent discussions with clinicians. The literature search focused on standard (100 units/mL) and concentrated (200 units/mL) insulin lispro product information [18], glide force (i.e., the amount of effort required to press the pen's injection button) [31], and patient perceptions of standard and concentrated insulin [32][33][34][35].…”

Section: Health State Developmentmentioning

confidence: 99%

“…The first and third of these differences are objective characteristics of the injection pens, as indicated in the Summary of Product Characteristics [18]. The second difference, ''effort to inject'' (i.e., glide force), has been examined in a previously published study, which found that the concentrated insulin pen required less effort (i.e., lower glide force) than the standard insulin pen [31].…”

Section: Health State Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Health State Developmentmentioning

confidence: 99%

Section: Health State Developmentmentioning

confidence: 99%

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…20 Recently developed concentrated insulins include insulin degludec (200 unit/mL formulation; Novo Nordisk, Bagsvaerd, Denmark), 21 insulin glargine (300 unit/ mL formulation; sanofi-aventis US LLC, Bridgewater, NJ, USA), 22 and insulin lispro (200 unit/mL; Eli Lilly and Company, Indianapolis, IN, USA). 23 The prefilled insulin delivery devices that contain these concentrated insulins dial and dose in actual units such that no conversion is needed based on the concentration. [21][22][23] The Humalog® 200 units/mL KwikPenTM.…”

mentioning

confidence: 99%

“…23 The prefilled insulin delivery devices that contain these concentrated insulins dial and dose in actual units such that no conversion is needed based on the concentration. [21][22][23] The Humalog® 200 units/mL KwikPenTM. (insulin lispro 200 units/mL, hereafter, IL 200 pen; Eli Lilly and Company, Indianapolis, IN, USA) insulin delivery device was recently approved in the US 24 and in the European Union.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin

Wang

Conrad

Brunt

et al. 2016

J Diabetes Sci Technol

Self Cite

View full text Add to dashboard Cite

Background: This study compared patient preference for Humalog® KwikPen™ 200 units/mL (insulin lispro; hereafter, IL 200 pen; Eli Lilly and Company, Indianapolis, IN) versus the Humalog KwikPen 100 units/mL (insulin lispro; hereafter, IL 100 pen; Eli Lilly and Company, Indianapolis, IN) in patients with diabetes requiring >20 units of mealtime insulin and diabetes caregivers. This study also determined which attributes had the greatest influence on pen preference selection. Methods: In this 2-period, crossover, simulated-use study, 106 participants were randomized to 1 of 8 sequences that varied the pen order (IL 100 pen or IL 200 pen) and dosing order (15 units = low dose or 50 units = high dose) for a total of 4 simulated injections. Participants then completed a self-administered questionnaire to select their overall preference between the 2 pens and then rated the importance of 11 pen attributes in contributing to their overall preference. Results: Of the 90 participants expressing an overall preference, significantly more preferred the IL 200 pen to the IL 100 pen (IL 200 pen: 80 respondents; IL 100 pen: 10 respondents; 95% confidence interval [0.81, 0.94], P < .0001). The total amount of insulin in the pen, the ease in pressing the injection button, and the amount of fluid injected were key attributes influencing IL 200 pen preference. Conclusions: Based on these key attributes, the IL 200 pen was significantly preferred over the IL 100 pen by patients with diabetes who require >20 daily mealtime insulin units or diabetes caregivers and may improve the injection experience for these patients.

show abstract

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

2018

View full text Add to dashboard Cite

Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65 years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities.FundingEli Lilly and Company.

show abstract

A Comparison of Glide Force Characteristics Between 2 Prefilled Insulin Lispro Pens

Cited by 16 publications

References 18 publications

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

Contact Info

Product

Resources

About